BioWorld MedTech

Jan. 27, 2016

View Archived Issues

Firm finds niche in cardiovascular monitoring: Irhythm finds its groove in both wearable, digital health markets

Hold placed on Califf nomination: Senate hostage-taking snares confirmation of FDA head

Ebola Lessons learned? Global organizations to speed Zika R&D

Financings: Minnetronix dips its toe in equity market with $20M raise

People in Places

Daily M&A: Perkinelmer completes acquisition of Vanadis

Agreements/contracts: Stereotaxis, Philips to continue cardiology procedure work

product briefs

Briefly noted

MDD's Oncology Extra

Funding to be used for host of trials: Cancer genomics firm Inivata pulls in $42M in series A funding

LONDON – Inivata Ltd. has raised £31.5 million (US$42.2 million) in a series A round, to advance the commercialization of its circulating tumor DNA liquid biopsy technology. Read More

Inside the Beltway: NICE offers favorable review of AMS's Greenlight for BPH

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...